These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 8653994)

  • 1. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics.
    Slayter KL; Ludwig EA; Lew KH; Middleton E; Ferry JJ; Jusko WJ
    Clin Pharmacol Ther; 1996 Mar; 59(3):312-21. PubMed ID: 8653994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers.
    Booker BM; Magee MH; Blum RA; Lates CD; Jusko WJ
    Clin Pharmacol Ther; 2002 Oct; 72(4):370-82. PubMed ID: 12386639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure.
    Tornatore KM; Venuto RC; Logue G; Davis PJ
    J Med; 1998; 29(3-4):159-83. PubMed ID: 9865456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dexamethasone suppression test and long-term contraceptive treatment: measurement of ACTH or salivary cortisol does not improve the reliability of the test.
    Nickelsen T; Lissner W; Schöffling K
    Exp Clin Endocrinol; 1989; 94(3):275-80. PubMed ID: 2560985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure.
    Jusko WJ; Milad MA; Ludwig EA; Lew KH; Kohli RK
    Clin Nephrol; 1995 Jan; 43 Suppl 1():S16-9. PubMed ID: 7781199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imipramine disposition in users of oral contraceptive steroids.
    Abernethy DR; Greenblatt DJ; Shader RI
    Clin Pharmacol Ther; 1984 Jun; 35(6):792-7. PubMed ID: 6734030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics.
    Lew KH; Ludwig EA; Milad MA; Donovan K; Middleton E; Ferry JJ; Jusko WJ
    Clin Pharmacol Ther; 1993 Oct; 54(4):402-14. PubMed ID: 8222483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardiovascular risks of oral contraceptives: dose-response relationship].
    Kelleher CC
    Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE; Anania C; Malinak R
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired elimination of caffeine by oral contraceptive steroids.
    Patwardhan RV; Desmond PV; Johnson RF; Schenker S
    J Lab Clin Med; 1980 Apr; 95(4):603-8. PubMed ID: 7359014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2.
    Granfors MT; Backman JT; Laitila J; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Oct; 78(4):400-11. PubMed ID: 16198659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.
    Varis T; Backman JT; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Mar; 67(3):215-21. PubMed ID: 10741623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.
    Barditch-Crovo P; Trapnell CB; Ette E; Zacur HA; Coresh J; Rocco LE; Hendrix CW; Flexner C
    Clin Pharmacol Ther; 1999 Apr; 65(4):428-38. PubMed ID: 10223781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
    Lidegaard O
    Acta Obstet Gynecol Scand; 1997 Mar; 76(3):252-60. PubMed ID: 9093141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased metabolic clearance of acetaminophen with oral contraceptive use.
    Abernethy DR; Divoll M; Ochs HR; Ameer B; Greenblatt DJ
    Obstet Gynecol; 1982 Sep; 60(3):338-41. PubMed ID: 6897933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylprednisolone and cortisol metabolism during the early post-renal transplant period.
    Tornatore KM; Reed KA; Venuto RC
    Clin Transplant; 1995 Dec; 9(6):427-32. PubMed ID: 8645883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adolescents' cortisol responses to awakening and social stress; effects of gender, menstrual phase and oral contraceptives. The TRAILS study.
    Bouma EM; Riese H; Ormel J; Verhulst FC; Oldehinkel AJ
    Psychoneuroendocrinology; 2009 Jul; 34(6):884-93. PubMed ID: 19195792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
    Griffith SG; Dai Y
    Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.